Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian cells

Biology of Reproduction

Volumn 86, Issue 3, 2012, Pages

  Roti, Elon C ^a   Salih, Sana M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Doxorubicin; Female infertility; Granulosa cells; Ovary; Premature ovarian failure

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; HISTONE H2A; HISTONE H2AFX; HYDROGEN PEROXIDE; RAZOXANE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; H2AFX PROTEIN, MOUSE; HISTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CELL LOSS; CELL PROTECTION; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; ENZYME ACTIVITY; FEMALE; GRANULOSA CELL; HORMONE SUBSTITUTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; REPRODUCTIVE PROCEDURE; STROMA CELL; THECA CELL; ANIMAL; ANIMAL MODEL; CELL CULTURE; CELL LINE; CYTOLOGY; DNA DAMAGE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE INFERTILITY; MOUSE STRAIN; OVARY; PHYSIOLOGY;

MURINAE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL LINE; CELLS, CULTURED; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; GRANULOSA CELLS; HISTONES; HYDROGEN PEROXIDE; INFERTILITY, FEMALE; MICE; MICE, INBRED STRAINS; MODELS, ANIMAL; OVARY; OXIDATIVE STRESS; RAZOXANE;

EID: 84860629089     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.111.097030     Document Type: Article

References (56)

1. Oktem O, Oktay K. Fertility preservation for breast cancer patients. Semin Reprod Med 2009; 27:486-492.
2. Hewitt M, Breen N, Devesa S. Cancer prevalence and survivorship issues: analyses of the 1992 National Health Interview Survey. J Natl Cancer Inst 1999; 91:1480-1486.
3. Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y, Robison LL, Sklar CA. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab 2006; 91:1723-1728.
4. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24:2917-2931.
5. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsk DA. Daunomycin an antitumor antibiotic in treatment of neoplastic disease-clinical evaluation with special reference to childhood leukemia. Cancer 1967; 20:333-353.
6. Ben-Aharon I, Bar-Joseph H, Tzarfaty G, Kuchinsky L, Rizel S, Stemmer SM, Shalgi R. Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol 2010; 8:20.
7. Perez GI, Knudson CM, Leykin L, Korsmeyer SJ, Tilly JL. Apoptosisassociated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Nat Med 1997; 3:1228-1232.
8. Bar-Joseph H, Ben-Aharon I, Rizel S, Stemmer SM, Tzabari M, Shalgi R. Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes. Reprod Toxicol 2010; 30:566-572.
9. Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 2000; 64:221-253.
10. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57:727-741.
11. Hasinoff BB, Schroeder PE, Patel D. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicininduced cytotoxicity. Mol Pharmacol 2003; 64:670-678.
12. Swift LM, Sarvazyan N. Localization of dichlorofluorescin in cardiac myocytes: implications for assessment of oxidative stress. Am J Physiol Heart Circ Physiol 2000; 278:H982-H990.
13. Alharbi MM, Algharably NM, Alshabanah OA, Albekairi AM, Osman AMM, Tawfik HN. Prevention of doxorubicin-induced myocardial and hematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemother Pharmacol 1992; 31:200-204.
14. Hershko C, Link G, Tzahor M, Kaltwasser JP, Athias P, Grynberg A, Pinson A. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine-studies in rat-heart cells in culture. J Lab Clin Med 1993;122:245-251.
15. Voest EE, Vanacker S, Vandervijgh WJF, Vanasbeck BS, Bast A. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 1994; 26:1179-1185.
16. Martin E, Thougaard AV, Grauslund M, Jensen PB, Bjorkling F, Hasinoff BB, Tjornelund J, Sehested M, Jensen LH. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology 2009; 255:72-79.
17. Herman EH, Ferrans VJ. Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy. Cancer Treat Rev 1990; 17:155-160.
18. Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, Knoblauch P, Rasmussen A, Dahlstrom K, Jensen PB, Giaccone G. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 2007;18:546-550.
19. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF. Topoisomerase II beta-mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007; 67:8839-8846.
20. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004; 130:1-7.
21. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15:1318-1332.
22. Fattman CL, Allan WP, Hasinoff BB, Yalowich JC. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)- resistant human leukemia K562 cells. Biochem Pharmacol 1996; 52:635-642.
23. Renodon-Corniere A, Jensen LH, Nitiss JL, Jensen PB, Sehested M. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance. Biochemistry 2003; 42:9749-9754.
24. Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AMA. QSAR study comparing the cytotoxicity and DNA topoisomerase-II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 1995; 50:953-958.
25. Classen S, Olland S, Berger JM. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci U S A 2003; 100:10629-10634.
26. Classen S, Olland S, Berger JM. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci U S A 2003; 100:14510.
27. Larsen AK, Eseargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003; 99:167-181.
28. Sehested M, Jensen PB. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 1996; 51:879-886.
29. Diop NK, Vitellaro LK, Arnold P, Shang MY, Marusak RA. Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity. J Inorg Biochem 2000; 78:209-216.
30. Hasinoff BB. Dexrazoxane (ICRF-187) protects cardiac myoctes against hypoxia-reoxygenation damage. Cardiovasc Toxicol 2002; 2:111-118.
31. Pouillart P. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. Cancer Treat Rev 2004; 30:643-650.
32. Pearlman M, Jendiroba D, Pagliaro L, Keyhani A, Liu BS, Freireich EJ. Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. Leuk Res 2003; 27:617-626.
33. Styczynski J, Wysocki M, Balwierz W, Kowalczyk JR. Dexrazoxane has no impact on sensitivity of childhood leukemic blasts to daunorubicin. Leukemia 2002; 16:820-825.
34. Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Larsen EC, Moghrabi A, Samson Y, Schorin MA, Cohen HJ, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 2008; 26:1106-1111.
35. Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Larsen EC, Laverdiere C, Michon B, Schorin M, et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer 2011; 47:1373-1379.
36. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007; 25:493-500.
37. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelber RD, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109:896-904.
38. Marty M, Espie M, Llombart A, Monnier A, Rapoport BL, Stahalova V. Dexrazoxane Study G. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol 2006; 17:614-622.
39. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuchjacquotte A, Wernz J, Feit F, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast-cancer. N Engl J Med 1988; 319:745-752.
40. Speyer JL, Green MD, Zeleniuchjacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, Blum RH, Feit F, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast-cancer. J Clin Oncol 1992; 10:117-127.
41. Testore F, Milanese S, Ceste M, de Conciliis E, Parello G, Lanfranco C, Manfredi R, Ferrero G, Simoni C, Miglietta L, Ferro S, Giaretto L, et al. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting. Am J Cardiovasc Drugs 2008; 8:257-263.
42. Olive PL, Banath JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the ''comet'' assay. Radiat Res 1990; 122:86-94.
43. Speth PAJ, Vanhoesel Q, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988; 15:15-31.
44. Paris F, Perez GI, Fuks Z, Haimovitz-Friedman A, Nguyen H, Bose M, Ilagan A, Hunt PA, Morgan WF, Tilly JL, Kolesnick R. Sphingosine 1- phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring. Nat Med 2002; 8:901-902.
45. Gonfloni S, Di Tella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C, Mattei M, Candi E, De Felici M, Melino G, Cesareni G. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med 2009; 15:1179-1185.
46. Jurisicova A, Lee HJ, D'Estaing SG, Tilly J, Perez GI. Molecular requirements for doxorubicin-mediated death in murine oocytes. Cell Death Differ 2006; 13:1466-1474.
47. Su YQ, Wu XM, O'Brien MJ, Pendola FL, Denegre JN, Matzuk MM, Eppig JJ. Synergistic roles of BMP15 and GDF9 in the development and function of the oocyte-cumulus cell complex in mice: genetic evidence for an oocyte-granulosa cell regulatory loop. Dev Biol 2004;276:64-73.
48. Barnabe N, Hasinoff BB. High-throughput fluorescence flow-injection topoisomerase II inhibition assay. J Chromatogr B 2001; 760:263-269.
49. Hasinoff BB, Creighton AM, Kozlowska H, Thampatty P, Allan WP, Yalowich JC. Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site. Mol Pharmacol 1997;52:839-845.
50. Wu X, Hasinoff BB. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of ironmediated reactive oxygen species. Anticancer Drugs 2005; 16:93-99.
51. Yan TD, Deng SW, Metzger A, Godtel-Armbrust U, Porter ACG, Wojnowski L. Topoisomerase II alpha-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin. Mol Cancer Ther 2009; 8:1075-1085.
52. Sargent JM, Williamson CJ, Yardley C, Taylor CG, Hellmann K. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562. Br J Cancer 2001; 84:959-964.
53. Budman DR, Calabro A. In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer Res Treat 2002; 74:41-46.
54. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1998; 1400:155-171.
55. Hofland KF, Thougaard AV, Sehested M, Jensen PB. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin Cancer Res 2005; 11:3915-3924.
56. Frederick CA, Williams LD, Ughetto G, Vandermarel GA, Vanboom JH, Rich A, Wang AHJ. Structural comparison of anticancer drug DNA complexes-adriamycin and daunomycin. Biochemistry 1990; 29:2538-2549.